関: manidipine hydrochloride

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/05/30 21:57:41」(JST)

wiki en

Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive.^[1]^[2]^[3]^[4]^[5]

Manidipine is marketed by:

-Greek Pharmaceutical group Chiesi Hellas under the brands Manyper, Artedil, Manivasc and Iperten (formerly sold by Torrex Pharma GmbH, now owned by Chiesi Hellas), in Germany, Greece, France, Austria, Spain, Italy and Brazil.

-Takeda Chemical Industries, under the brands Vascoman, Calslot, and Madiplot, in Italy, Japan, Philippines and Thailand.

References [edit]

^ Cheer, S.M.; McClellan, K. (2001), "Manidipine: A Review of its Use in Hypertension", Drugs 61 (12): 1777–99, PMID 11693466, retrieved 2009-06-20
^ McKeage, K.; Scott, L.J. (2004), "Manidipine: A Review of its Use in the Management of Hypertension", Drugs 64 (17): 1923–40, PMID 15329044, retrieved 2009-06-20
^ Roca-cusachs, A.; Triposkiadis, F. (2005), "Antihypertensive Effect of Manidipine", Drugs 65: 11–9, PMID 16398058, retrieved 2009-06-20
^ Otero, M.L. (2007), "Manidipine–delapril combination in the management of hypertension", Vascular Health and Risk Management 3 (3): 255–63, PMC 2293964, PMID 17703633
^ Mizuno, Kenji; Hiroshi Haga, Michihiko Takahashi, Soitsu Fukuchi (1992-08), "Evaluation of manidipine hydrochloride, a new calcium antagonist, in the treatment of hypertensive patients with renal disorders", Current Therapeutic Research 52 (2): 248–253, doi:10.1016/S0011-393X(05)80475-8, retrieved 2009-06-20

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

English Journal

Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions.

Uesawa Y, Takeuchi T, Mohri K.SourceClinical Pharmaceutics Laboratory, Department of Pharmaceutics, Meiji Pharmaceutical University 2- 522-1 Noshio, Kiyose, Tokyo 204-8588, Japan. uesawa@my-pharm.ac.jp.
Current pharmaceutical biotechnology.Curr Pharm Biotechnol.2012 Jul 1;13(9):1705-17.
Concomitant consumption of grapefruit juice (GFJ) causes increases in the plasma concentration of a variety of drugs due to inhibition of intestinal CYP3A enzyme. Dihydropyridine calcium channel blockers belong to the category of drugs that are most prone to undergo such interaction. Increases in ar
PMID 22039822

Quantitative structure-interaction relationship analysis of 1,4-dihydropyridine drugs in concomitant administration with grapefruit juice.

Uesawa Y, Mohri K.SourceClinical Pharmaceutics Laboratory, Department of Pharmaceutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo 204-8588, Japan. uesawa@my-pharm.ac.jp
Die Pharmazie.Pharmazie.2012 Mar;67(3):195-201.
Quantitative structure-interaction relationship (QSIR) analyses of 1,4-dihydropyridine drugs were performed on grapefruit juice interaction potentials to characterize the interaction and evaluate drugs not yet tested in clinical research. AUC ratios of drugs with and without grapefruit juice ingesti
PMID 22530299

Japanese Journal

アムロジピンの関与が疑われる腹水貯留を来したSLEの1例

日本小児腎臓病学会雑誌 24(2), 230-235, 2011
NAID 130002114191

Plasma Renin Activity and Aldosterone Concentration are not Altered by the Novel Calcium Channel Antagonist, Azelnidipine, in Hypertensive Patients

Internal Medicine 49(7), 637-643, 2010
NAID 130000251780

nteractions between Grapefruit Juice and Calcium Channel Antagonists

Yonago Acta medica 52(1), 1-9, 2009-03
NAID 110007035312

「マニジピン」

Manidipine
Systematic (IUPAC) name
	2-[4-(diphenylmethyl)piperazin-1-yl]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	℞ Prescription only
Identifiers
CAS number	89226-50-6 120092-68-4
ATC code	C08CA11
PubChem	CID 4008
ChemSpider	3868
UNII	6O4754US88
Chemical data
Formula	C35H38N4O6
Mol. mass	610.69 g/mol
	SMILES [O-][N+](=O)c1cccc(c1)C5C(/C(=O)OC)=C(\N\C(=C5\C(=O)OCCN4CCN(C(c2ccccc2)c3ccccc3)CC4)C)C;